Abstracts tagged "Cardiovascular"

Abstract Number: 2219 • ACR Convergence 2022
Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Punyasha Roul⁴, Ted Mikuls⁵, Daniel Clauw⁶, Bryant England⁷, Joshua Baker⁸, Brian Sauer⁹, Grant Cannon¹⁰, Shirley Cohen-Mekelberg¹, Wyndy Wiitala², Jeremy Sussman¹, Rodney Hayward¹ and Akbar Waljee¹, ¹University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, ⁴UNMC, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Michigan Department of Anesthesia, Ann Arbor, MI, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
Abstract Number: 0251 • ACR Convergence 2022
Nuclear Factor of Activated T Cells Cytoplasmic 1 as a Potential Biomarker of Increased Cardiovascular Risk in Patients with Early Rheumatoid Arthritis
Sara Remuzgo-Martinez¹, Fernanda Genre¹, Veronica Pulito-Cueto², Alfonso Corrales¹, Virgi Portilla¹, Leticia Lera-Gómez¹, Belén Atienza-Mateo¹, María Sebastián Mora-Gil¹, J Gonzalo Ocejo-Vinyals³, Oreste Gualillo⁴, Ricardo Blanco⁵, Ivan Ferraz Amaro⁶, Santos Castañeda⁷, Raquel Lopez Mejias² and Miguel Ángel González-Gay⁸, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²IDIVAL, Santander, Spain, ³Department of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ⁷Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁸Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: NFKB1, NKIRAS1, NFATc1, NFATc2 and MTHFR, inflammation and immune response-related genes, predispose to the increased risk of cardiovascular (CV) disease in patients with RA…
Abstract Number: 0575 • ACR Convergence 2022
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis
Leslie Spangler¹, Carrie Nielson¹, M Alan Brookhart², Rohini K Hernandez¹, Robert Kees Stad³ and Jay Lin¹, ¹Amgen, Inc., Thousand Oaks, CA, ²NoviSci, Inc., Durham, NC, ³Amgen Inc., Zug, Switzerland
Background/Purpose: There has been inconsistent evidence published regarding the cardio- and cerebrovascular benefits and risks of anti-osteoporosis medications. EU regulators requested Amgen to evaluate the…
Abstract Number: 0909 • ACR Convergence 2022
Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera¹, Tomás Cerdó², Maria Luque-Tevar³, Pilar Font¹, Montserrat Romero-Gomez², Desiree Ruiz-Vilchez⁴, Sara Remuzgo-Martinez⁵, Raquel Lopez Mejias⁶, María Carmen Ábalos-Aguilera⁷, Rafaela Ortega-Castro¹, José Perez-Venegas⁸, Mª Dolores Ruiz-Montesinos⁸, Carmen Dominguez⁸, Carlos Rodriguez-Escalera⁹, Carmen Romero-Barco⁹, Antonio Fernandez-Nebro¹⁰, Natalia Mena Vazquez¹⁰, Jose Luis Marenco¹¹, Julia Uceda Montañez¹¹, Charo Santos¹², Nuria Barbarroja¹, Mª Angeles Aguirre¹³, Alejandro Escudero-Contreras², Eduardo Collantes¹, Miguel Ángel González-Gay¹⁴ and Carlos Pérez-Sánchez¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ³IMIBIC, Córdoba, Spain, ⁴Reina Sofia University Hospital, Cordoba, Cordoba, Spain, ⁵Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶IDIVAL, Santander, Spain, ⁷Imibic/ University of Córdoba/ Reina Sofía Hospital, Córdoba, Spain, ⁸Virgen Macarena University Hospital, Sevilla, Spain, ⁹Virgen de la Victoria Hospital, Málaga, Spain, ¹⁰Regional University Hospital of Málaga, Málaga, Spain, ¹¹Virgen de Valme University Hospital, Sevilla, Spain, ¹²Virgen de Valme University Hospital, Málaga, Spain, ¹³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain, ¹⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: This study aimed to 1) Analyze the circulating inflammatory profile of Rheumatoid Arthritis (RA) patients, in order to recognize distinctive clinical phenotypes associated with…
Abstract Number: 1391 • ACR Convergence 2022
Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
Tooba Munawar¹, Farzam Khokhar² and Andras Perl³, ¹SUNY Upstate Medical Unviersity, Jamesville, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Patients with RA are at risk of accelerated cardiovascular disease (CVD). The purpose of this study…
Abstract Number: 1578 • ACR Convergence 2022
Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis
Francis Lao¹, Cal Robinson², Megan Schlorff¹, Joycelynn Ewusie³, KAREN BEATTIE¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²The Hospital for Sick Children, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited…
Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Ernesto Tovar-Sugrañes, Maria-Carmen Lopez-Gonzalez, Cristina Rodriguez-Alvear, Elisabet Perea-Martinez and Mariano Andrès, Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…
Abstract Number: 2270 • ACR Convergence 2022
Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Lida Kabir, Robert Maughan, Koralia Paschalaki, Anna Randi, David Carling, Deepa Arachchillage, Justin Mason and Charis Pericleous, Imperial College London, London, United Kingdom
Background/Purpose: The endothelium is a major target of pathogenic antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). It is well established that aPL…
Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Katherine Liao¹, Jon Giles², Pamela Rist¹, Robert Glynn¹, Leah Santacroce¹, Paul Ridker¹, Ahmed Tawakol³, Joan Bathon² and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…
Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Meena Afroze Shanta¹, Farheen Sultan Shaikh², Bhanupriya Madarampalli³ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…
Abstract Number: 0921 • ACR Convergence 2022
Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Ivan Arias-de la Rosa¹, Miriam Ruiz-Ponce¹, Laura Cuesta-Lopez¹, Rafaela Ortega-Castro¹, Jerusalem Calvo¹, lourdes Ladehesa-Pineda², Carlos Pérez-Sánchez¹, Chary López-Pedrera³, Eduardo Collantes¹, Alejandro Escudero-Contreras¹ and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Methotrexate (MTX) is the first-line treatment in Rheumatoid arthritis (RA) patients. To date, the evidence about the liver disease caused by MTX is controversial.…
Abstract Number: 1400 • ACR Convergence 2022
Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Tate Johnson¹, Rebekah Gundry², Merry Lindsey², Punyasha Roul³, Yangyuna Yang², Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Geoffrey Thiele², Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in patients with rheumatoid arthritis (RA). General population CVD risk calculators underestimate risk in RA,…
Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Tate Johnson¹, Lindsay Helget², Harlan Sayles², Punyasha Roul³, James O'Dell², Ted Mikuls⁴ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
Abstract Number: 1846 • ACR Convergence 2022
Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
Patrick Webster¹, Yogita Rochlani² and Konstantinos Loupasakis³, ¹Rheumatology Fellow at Montefiore, New York, NY, ²Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, ³Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Cardiac sarcoidosis (CS) is potentially life-threatening and it typically causes heart failure, ventricular arrhythmia, AV block or sudden death. CS has been reported to…
Abstract Number: 0257 • ACR Convergence 2022
High Density Lipoprotein Bound miR-1246 Is Enriched in Patients with Rheumatoid Arthritis and Is Proinflammatory
Qiong Wu, Quanhu Sheng, Danielle Michell, Kasey Vickers and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: High density lipoprotein (HDL) is known for its anti-atherogenic cholesterol efflux and antioxidant functions. HDL has additional relevance to rheumatoid arthritis (RA) because of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].